5.45
price down icon10.66%   -0.65
after-market Handel nachbörslich: 5.56 0.11 +2.02%
loading
Schlusskurs vom Vortag:
$6.10
Offen:
$6.08
24-Stunden-Volumen:
126.49K
Relative Volume:
1.46
Marktkapitalisierung:
$91.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.88M
KGV:
-5.5612
EPS:
-0.98
Netto-Cashflow:
$-10.29M
1W Leistung:
-16.92%
1M Leistung:
-19.73%
6M Leistung:
-24.93%
1J Leistung:
-40.50%
1-Tages-Spanne:
Value
$5.45
$6.11
1-Wochen-Bereich:
Value
$5.45
$6.72
52-Wochen-Spanne:
Value
$4.75
$10.24

Coya Therapeutics Inc Stock (COYA) Company Profile

Name
Firmenname
Coya Therapeutics Inc
Name
Telefon
650.739.3939
Name
Adresse
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
COYA's Discussions on Twitter

Vergleichen Sie COYA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
COYA
Coya Therapeutics Inc
5.45 91.15M 0 -14.88M -10.29M -0.98
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
474.62 121.88B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
573.45 62.69B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
555.11 33.86B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
235.74 30.51B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
238.51 25.69B 3.81B -644.79M -669.77M -6.24

Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-12-04 Eingeleitet D. Boral Capital Buy

Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten

pulisher
Apr 02, 2025

Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe

Apr 01, 2025
pulisher
Mar 31, 2025

GMP Production of Exosomes Slated for Later This Year - streetwisereports.com

Mar 31, 2025
pulisher
Mar 29, 2025

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports

Mar 28, 2025
pulisher
Mar 28, 2025

What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo Finance

Mar 27, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe

Mar 26, 2025
pulisher
Mar 26, 2025

Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

(COYA) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 19, 2025

Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Secures $18.85M Funding, Reports Breakthrough in Alzheimer's Treatment - Stock Titan

Mar 18, 2025
pulisher
Mar 15, 2025

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire

Mar 15, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

Where are the Opportunities in (COYA) - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 11, 2025

Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Market Watch Highlights: Coya Therapeutics Inc (COYA) Ends on an Upturn Note at 6.88 - The Dwinnex

Mar 10, 2025
pulisher
Mar 08, 2025

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases - MSN

Mar 08, 2025
pulisher
Mar 06, 2025

ALS drug failures and why COYA 302 is different - Digital Journal

Mar 06, 2025
pulisher
Mar 04, 2025

Coya Therapeutics (NASDAQ:COYA) Trading Up 4.5% – Should You Buy? - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

(COYA) Investment Analysis - Stock Traders Daily

Mar 03, 2025
pulisher
Feb 25, 2025

Can GLP-1 Agonists Transform Alzheimer's Treatment? Coya Therapeutics Experts Weigh In - StockTitan

Feb 25, 2025
pulisher
Feb 22, 2025

Coya reports promising Alzheimer's treatment study results - MSN

Feb 22, 2025
pulisher
Feb 20, 2025

Long Term Trading Analysis for (COYA) - Stock Traders Daily

Feb 20, 2025
pulisher
Feb 20, 2025

Robust Growth in AI in Clinical Trials Market (2025-2032): - openPR

Feb 20, 2025
pulisher
Feb 14, 2025

Newbridge Financial Services Group Inc. Makes New Investment in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat

Feb 14, 2025
pulisher
Feb 10, 2025

Coya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from D. Boral Capital - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

Coya Therapeutics (NASDAQ:COYA) Receives Buy Rating from Chardan Capital - MarketBeat

Feb 10, 2025
pulisher
Feb 10, 2025

(COYA) Trading Advice - Stock Traders Daily

Feb 10, 2025
pulisher
Feb 09, 2025

BTIG maintains Coya Therapeutics stock buy rating, $15 target - MSN

Feb 09, 2025
pulisher
Feb 07, 2025

Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD (NASDAQ:COYA) - Seeking Alpha

Feb 07, 2025
pulisher
Feb 07, 2025

Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha

Feb 07, 2025
pulisher
Feb 07, 2025

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's disease - Marketscreener.com

Feb 07, 2025
pulisher
Feb 07, 2025

Coya Therapeutics Inc (COYA) Shares Rise Despite Market Challenges - The News Heater

Feb 07, 2025
pulisher
Feb 07, 2025

Why Is Coya Therapeutics Stock Trading Higher Today?Coya Therapeutics (NASDAQ:COYA) - Benzinga

Feb 07, 2025
pulisher
Feb 07, 2025

Coya reports promising Alzheimer’s treatment study results By Investing.com - Investing.com Nigeria

Feb 07, 2025

Finanzdaten der Coya Therapeutics Inc-Aktie (COYA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Coya Therapeutics Inc-Aktie (COYA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Swaminathan Arun
Chief Executive Officer
Nov 13 '24
Buy
7.36
5,000
36,797
10,000
Grossman Fred
Chief Medical Officer
Nov 11 '24
Buy
7.37
2,710
19,973
2,710
Swaminathan Arun
Chief Executive Officer
Nov 11 '24
Buy
7.34
5,000
36,689
5,000
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):